Trial reportDrug design, development and therapy2025
Comparison of Hemodynamic Status with Three Different Doses of Lidocaine as an Adjunct to Propofol-Remifentanil During Endotracheal Intubation in Elderly Female Patients: A Prospective Randomized Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lidocaine was reported to stabilize the hemodynamic status and reduce the incidence of postinduction hypotension in elderly patients. However, the optimal dose of lidocaine as an adjuvant to propofol-remifentanil during endotracheal intubation in elderly female patients remains uncertain. In this study, we aimed to determine the optimal dose of lidocaine as an adjuvant for propofol-remifentanil in elderly female patients. Methods: Two hundred and forty patients were randomly assigned to one of three groups in a ratio of 1:1:1, each receiving a different dosage of lidocaine: 0.5 mg/kg, 1.0 mg/kg, or 1.5 mg/kg, with propofol-remifentanil for endotracheal intubation. Patients' hemodynamic parameters were continuously monitored 10 minutes after the induction of anesthesia. Hypotension, defined as a mean arterial pressure <70% of the baseline value and/or <65 mm Hg, and treated with norepinephrine 4 μg, repeated as necessary. Norepinephrine consumption (primary outcome), mean arterial pressure, heart rate, and propofol consumption were recorded. Results: The incidence of hypotension was 51.4% (37/72), 13.0% (9/69), and 13.8% (9/65) in Groups 0.5, 1.0, and 1.5, respectively. The median (25th and 75th quartiles) consumption of norepinephrine was 4 (0-4) μg, 0 (0-0) μg, and 0 (0-0) μg across the groups, respectively; there was a significant difference among the groups (p = 0.0006). The incidence of hypertension was 15.7% (11/72), 5.8% (4/69), and 6.2% (4/65) across the groups, respectively. Conclusion: In summary, under the conditions of this study, we propose that 1.0 mg/kg lidocaine may be considered as an optimal dose when used as an adjuvant to propofol-remifentanil for endotracheal intubation. Clinical Trial Registration: Chinese Clinical Trial Registry number: ChiCTR2400092990 https://www.chictr.org.cn/bin/project/edit?pid=231367.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.